Researchers in the Cedars - Sinai Samuel Oschin Comprehensive Cancer Institute eradicated solid
tumors in laboratory mice using a novel combination of two targeted agents.
Not exact matches
«Despite the low infection levels of
mouse cells with oHSV, we were able to cause a delay
in tumor growth
in one of the cancer models and even cure many of the
mice in a second model,» said first author Jennifer Leddon, who conducted much of the
laboratory work during a research experience
in the Center for Childhood Cancer and Blood Diseases.
In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory mic
In their research, scientists at Rutgers created animal models that closely resemble the cancerous
tumors found
in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory mic
in women with ovarian cancer by injecting
tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into
laboratory mice.
«Eliminating endothelial CD146 by conditional knockout
in two different
mouse models of colitis significantly reduced the severity of inflammation and decreased
tumor incidence and
tumor progression
in a
mouse model of CAC,» reports lead investigator Xiyun Yan, PhD, from the Key
Laboratory of Protein and Peptide Pharmaceuticals, Institute of Biophysics, Chinese Academy of Sciences, Beijing.
The
mice were developed
in Roussel's
laboratory and are a powerful tool for testing the effectiveness of drugs against human
tumors.
Researchers demonstrated that the drugs pemetrexed and gemcitabine killed cells from
mouse and human brain
tumors, called group 3 medulloblastoma, growing
in the
laboratory.
Additionally, organizations such as Freiburg - based Oncotest, a company founded and directed by Fiebig, and the Jackson
Laboratory in Bar Harbor, Maine, provide access to a wide range of PDX
mice made from donated
tumor tissue.
Finally, Dr. Goldenring's
laboratory is also investigating the role of Rab25 as a
tumor suppressor
in the colon using the Rab25 - / -; Smad3 + / -
mouse model, which develops spontaneous invasive distal colon cancers.
Gold nanotubes engineered to a specified length, modified surfaces, and to have other desirable characteristics showed expected abilities to enter
tumor cells
in laboratory studies, and to distribute to tissues within live
mice as intended.
Yasuaki Tamura, working with colleagues
in the
laboratory of Pramod Srivastava, demonstrates that
tumor - derived heat shock protein - peptide vaccines can be used to treat a wide array of pre-existing
tumors in mice.
These days,
mice grafted with human
tumors, known as patient - derived xenograft (PDX)
mice, are common
in cancer research
laboratories.
On the contrary, recent evidence indicates that XMRV is a contaminant originating from the recombination of two
mouse endogenous retroviruses during passaging of a prostate
tumor xenograft (CWR22)
in mice, generating
laboratory - derived cell lines that are XMRV - infected.